WO1995007099A1 - Vaccin et procede pour sa production - Google Patents

Vaccin et procede pour sa production Download PDF

Info

Publication number
WO1995007099A1
WO1995007099A1 PCT/JP1994/001469 JP9401469W WO9507099A1 WO 1995007099 A1 WO1995007099 A1 WO 1995007099A1 JP 9401469 W JP9401469 W JP 9401469W WO 9507099 A1 WO9507099 A1 WO 9507099A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotide sequence
sequence encoding
protein
pathogen
vaccine
Prior art date
Application number
PCT/JP1994/001469
Other languages
English (en)
Japanese (ja)
Inventor
Kuniaki Nerome
Mitsuru Chiba
Atsushi Endo
Original Assignee
The Nisshin Oil Mills, Ltd.
Daiichi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Nisshin Oil Mills, Ltd., Daiichi Pharmaceutical Co., Ltd. filed Critical The Nisshin Oil Mills, Ltd.
Publication of WO1995007099A1 publication Critical patent/WO1995007099A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a vaccine and a method for producing the vaccine.
  • An object of the present invention is to provide an excellent actin that remarkably induces cell-mediated immunity in addition to humoral immunity. Disclosure of the invention
  • the present inventor found that the gene encoding the influenza virus HA protein could be derived from pathogens such as HIV-derived peptides. It has been found that the above problem can be solved by inserting a DNA encoding the product into a vector having a strong promoter, particularly a vaccinia virus, and inserting this nucleotide sequence into a vector having a strong promoter.
  • the present invention has been completed based on the above findings.
  • the present invention relates to a vaccine comprising a vaccinia virus, which is a vector into which a nucleotide sequence encoding a part or the entire length of the HA protein of an influenza virus and a nucleotide sequence encoding a part or the whole of a pathogen-derived product are incorporated. Thing.
  • a vaccine in which a nucleotide sequence encoding a pathogen-derived substance is inserted into DNA encoding a loop region of HA protein of influenza virus; and Wakuchin nucleotide sequence encoding a pathogen-derived product is a nucleotide sequence comprising at least 24 bases encoding the E emissions base rope protein g P 120 or gpl60 of HIV are provided; vaccine but is antigenic material derived from HIV .
  • a method for producing the above-mentioned vaccine a method for immunizing with the above-mentioned vaccine to induce cell-mediated immunity; and (a) immunizing with the above-mentioned vaccine A) further boosting with a chimeric protein expressed in a baculovirus-silkworm system, comprising a portion corresponding to part or all of the HA protein of the influenza virus and a portion corresponding to the antigenic substance desired to be immunized. Immunization methods are provided. BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 is a diagram showing one example of a vaccine production scheme of the present invention. BEST MODE FOR CARRYING OUT THE INVENTION
  • the vaccine of the present invention includes a nucleotide sequence encoding a part or the full length of the HA protein of influenza virus. According to the vaccine of the present invention, it is preferable to insert a nucleotide sequence encoding a part or the whole of a pathogen-derived substance into DNA encoding the loop region of the HA protein of influenza virus.
  • the gene encoding influenza virus HA protein (influenza The HA virus) is divided into 14 subtypes. Antigen mutations are also observed in these subtypes, but this tendency is particularly pronounced in viruses that are endemic in humans.
  • the region in which amino acid mutations frequently occur between strains is a region with few functional restrictions, and an example of this region is an HA loop region.
  • Examples of the DNA encoding the pathogen-derived product include DNAs derived from various viruses and tumors requiring immunity. More specifically, examples of such DNA include DNA derived from influenza virus, poliovirus, herpes virus, HIV, hepatitis B virus, hepatitis C virus, and DNA derived from tumors such as melanoma. And Plasmodium merozoite surface protein-1 (MSP-1) epitopes: Journal of Immunology, pp.3483-3490, 1994. . Particularly preferred DNAs are those encoding a disease virus that can be effectively treated and prevented by cellular immunity (ie, HIV, hepatitis B virus, hepatitis C virus, etc.).
  • the DNA encoding the pathogen-derived product only needs to be long enough to induce immunity. For example, it is appropriate to select a base encoding at least 8 amino acids to induce cell-mediated immunity and 13 or more amino acids to induce humoral immunity. For each pathogen, the site and length most suitable for inducing immunity should be selected according to the purpose of prevention or treatment.
  • an HIV-derived antigenic substance for example, gpl60 or gpl20 of the HIV envelope protein (envelope glycoprotein) can be used, and DNA encoding a part or the entire length of the evening protein is replaced with a part of the influenza virus HA protein or What is necessary is just to combine with the base sequence which codes a full length.
  • a tanno having an HIV epitope on the surface of an HA molecule without disrupting the peptide molecule structure containing the HIV epitope by inserting the HIV V3 loop into the loop region of the HA protein.
  • the molecular structure can be constructed. This The HIV loop peptide is suitable because it consists of a region mainly recognized by HIV neutralizing antibodies and cytotoxic T cells, and can be expected to induce both humoral immunity and cellular immunity.
  • the Xinnia virus which is more effective against systemic infection, is most suitable, and is particularly advantageous for the formation of cellular immunity.
  • Adenovirus and the like can also be used. It is appropriate to incorporate the foreign gene into a locus encoding a region not essential for vaccinia virus, such as a region encoding vaccinia virus thymidine kinase ( ⁇ ) or hemagglutinin ( ⁇ ).
  • a multivalent vaccine can be produced by incorporating two or more foreign genes into a viral vector.
  • vaccinia virus vectors necessary promoters, and methods for their recombination are known (proteins, nucleic acids, enzymes, 35 (14), 2432-2442, 1990; 37 (3), 440-454, 1990). 1992 etc.), and these known materials and methods may be used.
  • vaccinia virus WR strain squirrel Yuichi strain and its temperature-sensitive strain, virion maturation-deficient mutant strain and the like available from ATCC and the like can be used.
  • vaccinia virus transfer vectors pSFBs having an ATI (cow pox type A inclusion body) promoter and one to several P7.5 promoters (Fimahashi et al., J. Virology, 65) , 5584-5588, 1991) can be expected to act as a strong promoter and provide good effects.
  • ATI cow pox type A inclusion body
  • the primary selection of recombinant Exinia virus can be performed by plaque assay using the hemagglutinating ability of Exinnia virus, and a single cloning method can be performed by ordinary cloning methods such as limiting dilution and enzyme-linked immunosorbent assay. You can get the virus.
  • Vaccination may be based on, for example, experience with smallpox vaccine. While preventive vaccines against HIV are important, it is generally difficult to develop vaccines that respond to severe antigenic variation. According to the present invention, it is intended to amplify a DNA region encoding a specific antigenic site of HIV infecting a patient by using a PCR method or the like, and to prepare a pectin corresponding to a peptide translated from this DNA. Can be.
  • Such vaccines and therapeutic methods using them are important embodiments of the present invention (see Example 4).
  • a recombinant virus vaccine When a recombinant virus vaccine is used, it is generally not preferable to use the same vaccine for booster immunization.
  • a nucleotide sequence encoding 12 amino acids (PNH I GPGRATAA) was synthesized by adding a base sequence encoding an amino acid of HA to 80 (H1N2).
  • the two oligonucleotides 38mer (5 '-CCC AATC AC ATAG GACCAGGCAGAGCAACGGCAGCATG-3,) and 34mer (5'-CT were synthesized (Applied Biosystems) so that the Haelll site was located at the 5 'end and the Sphl site was located at the 3' end. Model 381A DNA synthesizer) ⁇ These two oligonucleotides were annealed.
  • the resulting DNA fragment is phosphorylated with T4 DNA kinase and fragmented. Used as B.
  • the plasmid pEH-HAl (FERM BP-2585) incorporating the HA gene of influenza virus A / sw / Ehime / 1/80 (H1N2) was cut with BamHI and Haelll, and HAs 1 to 452 Fragment A having the second base sequence was isolated.
  • Fragment A and fragment B were ligated using T4 DNA ligase to obtain fragment A + B. This fragment was further ligated with fragment C and T4 DNA ligation, and then treated with Acc I to remove extra terminal bases to produce a chimeric HA gene HA-MN.
  • Both cohesive ends of the HA-MN (BamHI site) were converted to blunt ends using T4-DNA polymerase.
  • the HA-MN gene and the vaccinia virus previously cleaved with Smal and dephosphorylated with bacterial alkaline phosphatase '' transfer vector pSFB5 (This transfer vector was obtained from Dr. Shida of the Institute for Virus Research, Kyoto University, Kyoto, Japan. Donated: See Funahashi et al., J. Virology, 65, 5584-5588, 1991.
  • This vector consists of five tandem promoter and ATI (cow pox A-type inclusion bodies).
  • the plasmid contains a 7.5-kDa synthetic promoter and a downstream restriction enzyme site for the transfer of a foreign gene.
  • FIG. 1 shows the above steps in a scheme. The nucleotide sequence of pCE-1 was confirmed by the dideoxy method using a primer (5'-TTTTGGGAAACCCAGAATGTGAA-3 ') corresponding to the HA gene (266 to 287).
  • Plasmid pCE-12 / g containing the chimeric HA gene was co-precipitated with the vaccinia virus WR strain DNA7.5 using the calcium phosphate method, and the resulting DNA was transferred to CV-1 cells (Dainippon Pharmaceutical Co., Ltd.). Company, Osaka, Japan) and homologous recombination was performed in the presence of vaccinia virus IBT D mutant (Virology, 155 ⁇ 97-105 (1986)).
  • Recombinant screening for vaccinia virus The hemagglutination ability of the influenza virus is masked with a specific antibody (anti-A / sw / HK / 1/74 ⁇ heron serum), and the plaque that has no hemagglutination ability is used. was isolated. Furthermore, a single virus was cloned by the limiting dilution method and the enzyme antibody method to obtain a recombinant vaccinia virus EA1-RVV.
  • Erythrocyte adsorption test enzyme antibody test on EA1-RVV-infected cells, indirect fluorescent antibody test, immunoprecipitation test, EA1-RVV on mice using chimeric HA molecule expressed by An immune response test (HI test) was performed.
  • Erythrocyte adsorption test R-13 (Dainippon Pharmaceutical Co., Osaka, Japan) Infect cells with EA1-RVV with moi 1, culture at 37 ° C for 24 hours, and allow cells to adsorb 1% chicken erythrocytes. Was. Cells were negative.
  • Enzyme antibody test RK-13 cells (3 ⁇ 10Vdish) were infected with EA1-RVV at 100 plaque / dish and cultured at 37 ° C. for 48 hours. Purified influenza virus A / sw / HK / 1/74 in incomplete Freund's adjuvant and emulsion was administered subcutaneously and intramuscularly to an antiserum (diluted 1: 100) from a heron as a primary antibody, HRP-labeled anti-heron Plaques were developed using an IgG (H + L) antibody (diluted 1: 100 in Cappel Laboratories) as a secondary antibody and 4-cloth-1-naphthol as a substrate. As a result, all plaques were stained purple-blue and positive.
  • Indirect fluorescent antibody test CV-1 cells (Dainippon Pharmaceutical Co., Ltd.) were cultured on an 18 ⁇ 18 round cover glass, and infected with EA1-RVV at moi 10 and cultured at 37 ° C. for 24 hours. 100-fold diluted anti-A / sw / HK / 1/7474 egret serum was used as a primary antibody, and 200-fold diluted FITC-labeled anti-Peagle IgG (H +) (Cappel Laboratories) was used as a secondary antibody. Fluorescence microscopy showed strong fluorescent findings in the form of dots on the infected cell surface, indicating that the chimeric HA molecule was expressed on the cell surface.
  • the absorbed chimeric HA-antibody binding molecule was immunoprecipitated with Protein A.
  • the precipitate was separated by SDS-polyacrylamide electrophoresis and subjected to autoradiography. As a result, a band was detected at a position corresponding to a molecular weight of 76 K. It was confirmed that the molecular weight at 76 K was almost the same as the molecular weight of the HA molecule of A / sw / HK / 1/74 and had the same size.
  • the HI antibody titer of the mouse immune serum was 32 after 1 week, 64 after 2 weeks, and 128 after 3 to 4 weeks, indicating an efficient increase in antibody.
  • HI titers of control-immunized mice infected with the wild-type vaccinia virus were 32 or less.
  • the expression of the HIV gene inserted into EA2-RVV was further confirmed by an enzyme antibody test and an indirect fluorescent antibody test using a synthetic peptide immune serum.
  • a peptide having the same sequence as the 15 amino acids derived from HIV encoded by the inserted gene fragment D was synthesized, and a conjugate was prepared by covalently linking hemocyanin (KLH) to the peptide.
  • the conjugate was administered to 2.5 kg female egrets.
  • complete Freund's adjuvant was used, and a 1.2 mg equivalent of KLH conjugate peptide was intradermally administered.
  • the second and third doses one week and two weeks later, the same amount of peptide as the first dose was administered intradermally using incomplete Freund's adjuvant. Serum samples were collected every other week after the first administration, and the increase in antibody titer was confirmed by ELISA.
  • RK-13 cells were infected with EA2-RVV. Serum obtained by peptide immunization (serum 3 weeks after the first immunization) was used as a primary antibody, HRP-labeled anti-Peagle IgG (H + L) antibody as a secondary antibody, and 4-cloth-1-naphthol as a substrate. The plaques formed were subjected to the reaction. As a result, all plaques were stained purple-blue and positive.
  • BALB / c (H-2 d ) mice were immunized with 10 7 / PFU / mouse of EA2-RVV administered via the tail vein. Five weeks later, lymphocytes were collected from the spleen (5 xlO 6 cells / ml), and the lymphocytes were added together with BALB / c 3T3 cells (2,5 xlO 5 cells / ml) into which the gp160 gene had been introduced in vitro. By culturing for 6 days, effector cells activated by secondary stimulation were obtained.
  • BALB / c 3T3 cells transfected with the gp160 gene (15-12) and BALB / c 3T3 cells (18 IIIBXTownsend) labeled with the synthetic peptide of the V3 region (RI QRGPGRAFVT I GK) of the HIV IIIB strain were used as target cells.
  • Cell, 44, 959-968, 1986) and unlabeled BALB / c 3T3 cells were used as controls.
  • the above effector cells (E) were added to these target cells ((T): 5 xlO 3 cells / well) (EZT ratio 20: 1, 40: 1. 80: 1), and the cytotoxicity was reduced to 51 Cr -Measured by the release method (Zweerink et al., Eur. J. Immunol., 7, pp. 630-635, 1977).
  • lymphocytes cytotoxic T cells sensitized by EA2-RVV were labeled with 15-12 cells presenting ⁇ 11 ⁇ 61 ⁇ protein or 18 II labeled with ⁇ pitide. High cytotoxic activity against IB cells. On the other hand, the lymphocytes did not show activity against BALB / c 3T3 used as a control.
  • the pectin of the present invention which is effective in this experiment, is effective in preventing the onset of disease and treating it by eliminating infected cells.
  • Table 1 CTL activity of EA2—RVV
  • a vector capable of expressing the HA chimeric protein was produced.
  • Plasmid PUC119 (Takara Shuzo) was digested with KpnI and SphII, and both ends of the obtained fragment were blunt-ended with T4 DNA polymerase.
  • the plasmid pEH-HAl (FERM-BP-2585) was digested with BamHI to extract the HA gene of influenza virus A / sw / Ehime / 1/80 (H1N2), and both ends were T4 DNA polymerase. And blunt ends.
  • plasmid pSK (-), which was then infected with M13K07phage to prepare single-stranded DNA.
  • the single-stranded DNA was annealed with a synthetic oligonucleotide GATATTCCCCGGGAC AAGTTCG having a SmaI site, and then treated with DNA polymerase to produce a double-stranded circular plasmid pAC-1.
  • this plasmid pAC-1 is digested with Sraa I and Sph I and blunt-ended with T4 DNA polymerase, various foreign genes can be inserted into plasmid pAC-1 to obtain a plasmid containing chimeric genes. I can do it.
  • this plasmid is treated with Puv II, a chimeric gene can be obtained, which is useful for introducing the chimeric gene into a pixia virus transfer vector or a baculovirus transfer vector.
  • the use of the vaccine of the present invention is expected to be effective in the treatment and prevention of various diseases by the production of humoral antibodies.
  • the vaccine of the present invention is useful because an effect by cell-mediated immunity can be expected.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention se rapporte à un vaccin contenant un virus de la vaccine qui est constitué par un vecteur, dans lequel sont incorporées une séquence de bases codant pour une partie ou pour la totalité de la protéine HA (hémagglutinine) du virus de la grippe ainsi qu'une autre séquence de bases codant pour une partie ou pour la totalité d'une substance dérivée d'agents patogènes. Il est possible d'incorporer dans un vecteur une séquence de bases obtenue par exemple par insertion d'une séquence de bases qui code pour la protéine d'enveloppe gp120 ou gp160 du virus VIH et qui contient au moins 24 unités de base à l'intérieur d'un ADN codant pour la région en boucle de la protéine HA du virus de la grippe. L'invention se rapporte également à un procédé pour produire un tel vaccin ainsi qu'à un procédé pour obtenir l'immunité cellulaire à l'aide de ce vaccin.
PCT/JP1994/001469 1993-09-09 1994-09-06 Vaccin et procede pour sa production WO1995007099A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24866093 1993-09-09
JP5/248660 1993-09-09

Publications (1)

Publication Number Publication Date
WO1995007099A1 true WO1995007099A1 (fr) 1995-03-16

Family

ID=17181445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1994/001469 WO1995007099A1 (fr) 1993-09-09 1994-09-06 Vaccin et procede pour sa production

Country Status (1)

Country Link
WO (1) WO1995007099A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062381A1 (fr) * 2001-02-05 2002-08-15 Hisamitsu Pharmaceutical Co., Inc. Vaccin a vecteur de baculovirus
WO2012137071A2 (fr) 2011-04-06 2012-10-11 Biovaxim Limited Compositions pharmaceutiques pour prévenir et/ou traiter une maladie provoquée par le vih chez des êtres humains

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500518A (ja) * 1982-11-30 1985-04-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
JPH03108480A (ja) * 1989-09-20 1991-05-08 Kokuritsu Yobou Eisei Kenkyusho Ｈａ蛋白の製造法
EP0546787A2 (fr) * 1991-12-11 1993-06-16 American Home Products Corporation Expression d'immunogènes spécifiques utilisant des antigènes viraux

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500518A (ja) * 1982-11-30 1985-04-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
JPH03108480A (ja) * 1989-09-20 1991-05-08 Kokuritsu Yobou Eisei Kenkyusho Ｈａ蛋白の製造法
EP0546787A2 (fr) * 1991-12-11 1993-06-16 American Home Products Corporation Expression d'immunogènes spécifiques utilisant des antigènes viraux

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KINICHIRO MIURA et al., "Proteins, Nucleic Acids, Enzymes Special issue Development of Protein Technology Vol. 37, No. 3", 10 February 1992, KYORITSU SUPPAN K.K., pages 440-454. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062381A1 (fr) * 2001-02-05 2002-08-15 Hisamitsu Pharmaceutical Co., Inc. Vaccin a vecteur de baculovirus
WO2012137071A2 (fr) 2011-04-06 2012-10-11 Biovaxim Limited Compositions pharmaceutiques pour prévenir et/ou traiter une maladie provoquée par le vih chez des êtres humains
EP3000476A1 (fr) 2011-04-06 2016-03-30 Biovaxim Limited Compositions pharmaceutiques pour prévenir et/ou traiter une maladie vih chez l'homme

Similar Documents

Publication Publication Date Title
Hanke et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
Green et al. C3d enhancement of neutralizing antibodies to measles hemagglutinin
Griffiths et al. Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag: V3 fusion
HUT65366A (en) Expression of specific immunogens using viral antigens
EP0677111B1 (fr) Nouvelles particules proteiniques
CA2035039C (fr) Poxvirus recombinant et vaccin dirige contre la proteine m des streptocoques
US20090220537A1 (en) Vaccine delivery system
US7847085B2 (en) Recombinant HIV-1 gp120 immunogen with three different V3 loops from viruses of different clades
Gedvilaite et al. Segments of puumala hantavirus nucleocapsid protein inserted into chimeric polyomavirus-derived virus-like particles induce a strong immune response in mice
US20220054625A1 (en) Immunogenic composition
RU2181379C2 (ru) Пептид (варианты) и способ его производства, фармацевтическое средство, антитело и способ его производства
NZ244126A (en) Sterile adjuvant-free pharmaceutical formulation comprising a particulate proteinaceous antigen
US6458362B1 (en) Recombinant VP2 parvoviral pseudo-particles encoding CTL or T-helper cell epitopes
Gómez et al. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector
JPH07145079A (ja) 組換えアデノウイルス・ワクチン
WO1995007099A1 (fr) Vaccin et procede pour sa production
Koletzki et al. DNA vaccination of mice with a plasmid encoding Puumala hantavirus nucleocapsid protein mimics the B-cell response induced by virus infection
EA025275B1 (ru) Способ, терапевтическая композиция, вакцинная комбинация и набор для терапевтического или профилактического лечения вич
JPH07170982A (ja) ワクチンおよびその製造方法
Reddy et al. Induction of immune responses against human papillomaviruses by hypervariable epitope constructs
WO1995009249A1 (fr) Vaccination per os des mammiferes
Paolazzi et al. Rabies vaccine: Developments employing molecular biology methods
Bharati Effect of plasmid size on the immune response to Japanese encephalitis virus DNA vaccine in mice
Collado et al. Chimeras between the human immunodeficiency virus (HIV-1) Env and vaccinia virus immunogenic proteins p14 and p39 generate in mice broadly reactive antibodies and specific activation of CD8+ T cell responses to Env
RU2194075C2 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pTBI-HBsAg, СОДЕРЖАЩАЯ ХИМЕРНЫЙ ГЕН TBI-HBsAg ПОД КОНТРОЛЕМ ПРОМОТОРА p7.5K ВИРУСА ОСПОВАКЦИНЫ, И ШТАММ РЕКОМБИНАНТНОГО ВИРУСА ОСПОВАКЦИНЫ, ВЫЗЫВАЮЩИЙ ИММУННЫЙ ОТВЕТ ПРОТИВ ВИЧ И ГЕПАТИТА B ЧЕЛОВЕКА В ОРГАНИЗМЕ ЖИВОТНЫХ

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN FI JP KR NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA